Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer

Life Sciences ◽  
2016 ◽  
Vol 151 ◽  
pp. 7-14 ◽  
Author(s):  
Chang-Lin Hsieh ◽  
Hon-Ping Ma ◽  
Chih-Ming Su ◽  
Yu-Jia Chang ◽  
Wan-Yu Hung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Migration ◽  
Histone Deacetylase ◽  
Poor Prognosis ◽  
Histone Deacetylase 8

scholarly journals Absence of AIF1L contributes to cell migration and a poor prognosis of breast cancer

2018 ◽  
Vol Volume 11 ◽  
pp. 5485-5498 ◽  
Author(s):  
Peipei Liu ◽  
Wenhui Li ◽  
Yuanyuan Hu ◽  
Youhong Jiang
Keyword(s):  
Breast Cancer ◽  
Cell Migration ◽  
Poor Prognosis

An HDAC8-Selective Fluorescent Probe for Imaging in Living Tumor Cell Lines and Tissue Slices

2021 ◽  
Author(s):  
Yinyu Yan ◽  
chaoqun huang ◽  
Yi Shu ◽  
Hongmei Wen ◽  
Chenxiao Shan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Cell ◽  
Cancer Cells ◽  
Histone Deacetylase ◽  
Therapeutic Target ◽  
Breast Cancer Cells ◽  
Neuroblastoma Cells ◽  
Tumor Cell Lines ◽  
Tissue Slices ◽  
Histone Deacetylase 8

The histone deacetylase 8 (HDAC8) used as therapeutic target for many cancers such as highly expressed in neuroblastoma cells and breast cancer cells. HDAC8- selective fluorescent probes needed to be...

scholarly journals Potentials of CCL21 and CBS as therapeutic approaches for breast cancer

2022 ◽  
Author(s):  
Jing Peng ◽  
Danhua Zhang
Keyword(s):  
Breast Cancer ◽  
Cell Migration ◽  
Poor Prognosis ◽  
Close Association ◽  
Scratch Test ◽  
Normal Breast ◽  
Breast Epithelial Cell ◽  
Epithelial Cell Line ◽  
The Poor ◽  
Breast Tissues

Objective: The present research set out to ascertain the roles of CCL21 and CBS in breast cancer (BC) cell biological behaviors and the relationship of CCL21 and CBS expression with the clinicopathological features of patients with BC. Methods: Immunohistochemistry of CCL21 or CBS was performed in 18 intraductal cancer tissues, 124 invasive BC tissues, 50 paraneoplastic tissues, 50 lobular hyperplasia tissues, and 30 normal breast tissues. For cell experiments, two human BC cell lines (MDA-MB-231 and MCF-7) and a human breast epithelial cell line (MCF-10A) were utilized to detect the expression of CCL21 and CBS. After loss- and gain-of-function assays for CCL21 or CBS, the expression of CBS and CCL21 was measured by qRT-PCR and Western blot. Additionally, BC cell proliferation was assessed by MTT assay and EdU staining, and BC cell migration was determined by scratch test and Transwell assay. Results: In the clinical data, the positive rate of CCL21 or CBS was significantly higher in invasive BC tissues than in intraductal BC tissues, lobular hyperplasia tissues, paraneoplastic tissues, and normal breast tissues (P < 0.05 or P < 0.01). CBS or CCL21 expression shared close association with the clinicopathological characteristic and the poor prognosis of BC patients. In cell experiments, overexpression of CCL21 or CBS enhanced the proliferative and migratory abilities of BC cells. Conclusion: CCL21 and CBS promoted BC cell migration and proliferation. CCL21 or CBS expression was strongly related to the poor prognosis of BC patients.

Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells

APOPTOSIS ◽  
2017 ◽  
Vol 22 (11) ◽  
pp. 1394-1403 ◽  
Author(s):  
Vijaya Rao Pidugu ◽  
Nagendra Sastry Yarla ◽  
Anupam Bishayee ◽  
Arunasree M. Kalle ◽  
Alapati Krishna Satya
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Histone Deacetylase ◽  
Breast Cancer Cells ◽  
Selective Inhibitor ◽  
Histone Deacetylase 8

The clinical significance of histone deacetylase-8 in human breast cancer

2021 ◽  
Vol 220 ◽  
pp. 153396
Author(s):  
Golebagh Rahmani ◽  
Saba Sameri ◽  
Nooshin Abbasi ◽  
Mohammad Abdi ◽  
Rezvan Najafi
Keyword(s):  
Breast Cancer ◽  
Histone Deacetylase ◽  
Clinical Significance ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Histone Deacetylase 8

scholarly journals ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer

2018 ◽  
Author(s):  
Avais M. Daulat ◽  
Pascal Finetti ◽  
Diego Revinski ◽  
Mônica Silveira Wagner ◽  
Luc Camoin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Migration ◽  
G Protein ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Molecular Signature ◽  
Breast Cancers ◽  
Nucleotide Exchange ◽  
Small G Protein ◽  
Proteomic Approach

AbstractBackgroundTriple-negative breast cancers are poor-prognosis tumors characterized by absence of molecular signature and are chemotherapy is still the only systemic treatment. Currently, research focus to identify biomarkers that may be usable for prognosis and/or for treatment, notably among the proteins involved in cell migration and metastatic capacity.MethodsWe used proteomic approach to identify protein complexes associated to PRICKLE1 and the mRNA expression level of the corresponding genes in a retrospective series of 8,982 clinically annotated patients with invasive primary breast cancer were assessed. Then, we characterize molecularly the interaction between PRICKLE1 and the guanine nucleotide exchange factor ECT2. Finally, experiments in Xenopus have been carrying out to determine their evolutionary conserved interaction.ResultsWe have identified a network of proteins interacting with the prometastatic scaffold protein PRICKLE1 that includes several small G-protein regulators involved in cell migration and metastasis. Combined analysis expression of PRICKLE1 and small G-protein regulators expression has a strong prognostic value in TNBC. We show that PRICKLE1 controls the activity of ECT2 on RAC1 signaling, a pathway required for cancer cell dissemination.ConclusionsThis work supports the idea that promigratory proteins, which are overexpressed in cancerous epithelium, are suitable pharmaceutical targets.

Sign in / Sign up

Export Citation Format

Share Document